This article is the second in a series tracing the evolution of Canada’s legislation. It reviews the developments leading up to the adoption of Bill C-9 in its final form, and analyzes its positive and negative aspects. Hopefully, other advocates can learn from this experience and other countries can avoid replicating the negative aspects as they implement the WTO Decision.
Steps forward, backward, and sideways: Canada’s bill on exporting generic pharmaceuticals – HIV/AIDS Policy and Law Review 9(3)
Author
Richard Elliott, Canadian HIV/AIDS Legal Network
Topics
Access to Medicines
Language
English, French